Illustration of tubulin directing tau and alpha-synuclein away from aggregates inside a neuron
Illustration of tubulin directing tau and alpha-synuclein away from aggregates inside a neuron
Изображение, созданное ИИ

Study: Tubulin can steer Tau and alpha-synuclein away from toxic clumps

Изображение, созданное ИИ
Проверено фактами

Researchers at Baylor College of Medicine report that tubulin—the building block of microtubules—can shift Tau and alpha-synuclein inside cellular condensates away from disease-linked aggregation and toward roles that support healthy neurons.

Scientists at Baylor College of Medicine say they have identified a possible new strategy for addressing processes linked to Alzheimer’s and Parkinson’s diseases, both of which are associated with harmful clumps of the proteins Tau and alpha-synuclein in the brain.

In a study published in Nature Communications, the researchers report that tubulin, a protein that forms the building blocks of microtubules, can reduce the tendency of Tau and alpha-synuclein to form damaging aggregates. Instead, tubulin appears to push the proteins toward activities tied to normal cell function, including microtubule assembly and stabilization.

“Tau and alpha-synuclein are well known for their roles in neurodegenerative diseases like Alzheimer’s and Parkinson’s,” said first author Dr. Lathan Lucas, a postdoctoral associate in Dr. Allan Ferreon’s lab, in a Baylor statement carried by ScienceDaily. Lucas added that when tubulin levels are low—something the researchers said has been reported in Alzheimer’s disease—microtubules are less abundant and the proteins can form toxic aggregates.

The team framed the work as an alternative to approaches aimed at preventing the formation of condensates—tiny droplets in cells where the proteins can carry out both healthy and harmful activities—because condensates also have important roles in normal cell biology.

“Our findings significantly shift tubulin's role in neurodegeneration, from a passive casualty of disease to an active protector against toxic protein aggregation,” Ferreon, an associate professor and co-corresponding author, said in the same statement. He added that increasing the available tubulin pool, rather than blocking droplet formation, could potentially curb toxic aggregation while preserving the proteins’ normal roles.

Other contributors listed by the research organization include co-first author Phoebe S. Tsoi, My Diem Quan, Kyoung-Jae Choi, and co-corresponding author Josephine C. Ferreon.

The research was supported by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health under grant R01 NS105874, the Welch Foundation under grant Q-2097-20220331, and the National Institute of General Medical Sciences (NIGMS) at the NIH under grant R01 GM122763.

Что говорят люди

Initial reactions on X to the Baylor College of Medicine study are sparse and mostly positive, with users sharing the findings and noting potential implications for Alzheimer's and Parkinson's treatments by redirecting Tau and alpha-synuclein away from toxic aggregates.

Связанные статьи

Oregon State scientists tracking copper-driven amyloid-beta clumping in real time using fluorescence anisotropy, with chelators reversing aggregation, in a high-tech lab.
Изображение, созданное ИИ

Oregon State researchers track copper-driven amyloid clumping in real time, testing a copper-selective chelator

Сообщено ИИ Изображение, созданное ИИ Проверено фактами

Oregon State University scientists report they have monitored, second by second, how copper ions promote aggregation of amyloid-beta—an Alzheimer’s-associated protein—and how different metal-binding molecules can disrupt or reverse that clumping, using a fluorescence anisotropy approach described in a study published in ACS Omega.

Researchers at the University of California, Riverside have proposed that amyloid beta disrupts tau protein function inside neurons, potentially triggering Alzheimer's disease. The findings challenge the focus on external plaques as the primary cause.

Сообщено ИИ

A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.

Researchers at Boston Children’s Hospital report that mutations commonly associated with clonal blood-cell expansion and some blood cancers were enriched in microglia-like immune cells in Alzheimer’s brains and were also detectable in matched blood samples. The Cell study proposes that age- or injury-related weakening of the blood-brain barrier could allow mutated blood immune cells to enter the brain, potentially amplifying inflammation and contributing to neurodegeneration.

Этот сайт использует куки

Мы используем куки для анализа, чтобы улучшить наш сайт. Прочитайте нашу политику конфиденциальности для дополнительной информации.
Отклонить